Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Abstract C080: The combination of MEK and MDM2 inhibitors demonstrates promising antitumor efficacy in MAPK altered patient-derived thyroid and colorectal cancer models

Seyed Pairawan, Kurt Evans, Scott Kopetz, Argun Akcakanat, Ming Zhao, Coya Tapia, Naifa Busaidy, Ecaterina Dumbrava, Funda Meric-Bernstam

Mol Cancer Ther (2019) 18 (12_Supplement): C080.

DOI: https://doi.org/10.1158/1535-7163.TARG-19-C080

Published: 01 December 2019

View article

Journal Articles

Abstract B003: Combinatorial therapies of neratinib for HER2-amplified cancer

Ming Zhao, Stephen Scott, Kurt Evans, Erkan Yuca, Turcin Saridogan, Mehmet E Demirhan, Bryce P Kirby, Scott Kopetz, Irmina Diala, Alshad S Lalani, Sarina A Piha-Paul, Funda Meric-Bernstam

Mol Cancer Ther (2019) 18 (12_Supplement): B003.

DOI: https://doi.org/10.1158/1535-7163.TARG-19-B003

Published: 01 December 2019

View article

Journal Articles

Abstract A167: Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors

Ecaterina Ileana Dumbrava, Kavitha Balaji, Kanwal Raghav, Milind Javle, Mariela Blum-Murphy, Blessy Sajan, Scott Kopetz, Russell Broaddus, Mark Routbort, Shubham Pant, Apostolia Tsimberidou, Vivek Subbiah, David S. Hong, Jordi Rodon Ahnert, Kenna Shaw, Sarina Piha-Paul, Funda Meric-Bernstam

Mol Cancer Ther (2018) 17 (1_Supplement): A167.

DOI: https://doi.org/10.1158/1535-7163.TARG-17-A167

Published: 01 January 2018

View article

Journal Articles

Abstract A012: Humanized patient-derived xenografts (PDXs) recapitulate clinical responses in microsatellite stable (MSS) and unstable (MSI-H) colorectal cancer (CRC)

Anna Capasso, Julie Lang, Todd M. Pitts, Christopher H. Lieu, Scott Kopetz, Sarah L. Davis, Kimberly Jordan, Stacey M. Bagby, Wells A. Messersmith, Roberta Pelanda, S. Gail Eckhardt

Mol Cancer Ther (2018) 17 (1_Supplement): A012.

DOI: https://doi.org/10.1158/1535-7163.TARG-17-A012

Published: 01 January 2018

View article

Journal Articles

Abstract A055: RSPO3 overexpression is a characteristic feature of signet ring gastrointestinal malignancies

Van Morris, Alexey Sorokin, Mariela Blum, Krittiya Korphaisarn, Jeannelyn Estrella, Leonardo Faoro, Min Wang, Stanley Hamilton, Ann M. Kapoun, Scott Kopetz

Mol Cancer Ther (2018) 17 (1_Supplement): A055.

DOI: https://doi.org/10.1158/1535-7163.TARG-17-A055

Published: 01 January 2018

View article

Journal Articles

Modeling of Patient-Derived Xenografts in Colorectal Cancer

Anastasia Katsiampoura, Kanwal Raghav, Zhi-Qin Jiang, David G. Menter, Andreas Varkaris, Maria P. Morelli, Shanequa Manuel, Ji Wu, Alexey V. Sorokin, Bahar Salimian Rizi, Christopher Bristow, Feng Tian, Susan Airhart, Mingshan Cheng, Bradley M. Broom, Jeffrey Morris, Michael J. Overman, Garth Powis, Scott Kopetz

Mol Cancer Ther (2017) 16 (7): 1435–1442.

DOI: https://doi.org/10.1158/1535-7163.MCT-16-0721

Published: 04 July 2017

View article

Includes: Supplementary data

Journal Articles

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

Mol Cancer Ther (2016) 15 (6): 1397–1404.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0712

Published: 02 June 2016

View article

Includes: Supplementary data

Journal Articles

Abstract C50: Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer

Vivek Subbiah, David S. Hong, Behrang Amini, Sarina Piha-Paul, Joanna Grace Fernandez, Siquing Fu, Apostolia M. Tsimberidou, Aung Naing, Filip Janku, Daniel D. Karp, Michael Overman, Cathy Eng, Scott Kopetz, Funda Meric-Bernstam, Gerald S. Falchook

Mol Cancer Ther (2015) 14 (12_Supplement_2): C50.

DOI: https://doi.org/10.1158/1535-7163.TARG-15-C50

Published: 01 December 2015

View article

Journal Articles

Abstract A36: Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer

Van Morris, Filip Janku, Helen Huang, Siqing Fu, Michael Overman, Sarina Piha-Paul, Vivek Subbiah, Bryan Kee, Apostolia Tsimbierdou, David Fogelman, Imad Shurieqi, Shanequa Manuel, Antonio Scamardo, Richard Lanman, Nicolas Sommer, David Hong, Scott Kopetz

Mol Cancer Ther (2015) 14 (12_Supplement_2): A36.

DOI: https://doi.org/10.1158/1535-7163.TARG-15-A36

Published: 01 December 2015

View article

Journal Articles

Abstract A76: Prospective evaluation of two-phase NGS platform coupled to active precision oncology decision support in the therapeutic management of patients with advanced cancers

Kenna R. Shaw, Scott Kopetz, Vijaykumar Holla, Beate C. Litzenburger, Walter Kinyua, Blessy Sajan, J. Jack Lee, Russell Broaddus

Mol Cancer Ther (2015) 14 (12_Supplement_2): A76.

DOI: https://doi.org/10.1158/1535-7163.TARG-15-A76

Published: 01 December 2015

View article

Journal Articles

Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs

Mol Cancer Ther (2014) 13 (12): 2876–2885.

DOI: https://doi.org/10.1158/1535-7163.MCT-14-0074

Published: 04 December 2014

View article

Includes: Supplementary data

Journal Articles

Cancer In Silico Drug Discovery: A Systems Biology Tool for Identifying Candidate Drugs to Target Specific Molecular Tumor Subtypes

F. Anthony San Lucas, Jerry Fowler, Kyle Chang, Scott Kopetz, Eduardo Vilar, Paul Scheet

Mol Cancer Ther (2014) 13 (12): 3230–3240.

DOI: https://doi.org/10.1158/1535-7163.MCT-14-0260

Published: 04 December 2014

View article

Journal Articles

Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations

Prasanth Ganesan, Filip Janku, Aung Naing, David S. Hong, Apostolia M. Tsimberidou, Gerald S. Falchook, Jennifer J. Wheler, Sarina A. Piha-Paul, Siqing Fu, Vanda M. Stepanek, J. Jack Lee, Rajyalakshmi Luthra, Michael J. Overman, E. Scott Kopetz, Robert A. Wolff, Razelle Kurzrock

Mol Cancer Ther (2013) 12 (12): 2857–2863.

DOI: https://doi.org/10.1158/1535-7163.MCT-13-0319-T

Published: 05 December 2013

View article

Includes: Supplementary data

Journal Articles

Abstract B35: Acquired KRAS mutations after anti-EGFR therapy partially derive from low-frequency clones detectable in the primary tumor.

Maria Pia Morelli, Michael Overman, Arvind Dasari, Ali Kazmi, Edoardo Vilar-Sanchez, Cathy Eng, Bryan Kee, Laurel Deaton, Chris Garrett, Frank Diehl, Dipen Maru, Philipp Angenendt, Scott Kopetz

Mol Cancer Ther (2013) 12 (11_Supplement): B35.

DOI: https://doi.org/10.1158/1535-7163.TARG-13-B35

Published: 01 November 2013

View article

Journal Articles

Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways

Laura S. Angelo, Ji Yuan Wu, Feng Meng, Michael Sun, Scott Kopetz, Ian E. McCutcheon, John M. Slopis, Razelle Kurzrock

Mol Cancer Ther (2011) 10 (11): 2094–2103.

DOI: https://doi.org/10.1158/1535-7163.MCT-11-0243

Published: 08 November 2011

View article

NARROW

Abstract C080: The combination of MEK and MDM2 inhibitors demonstrates promising antitumor efficacy in MAPK altered patient-derived thyroid and colorectal cancer models

Abstract B003: Combinatorial therapies of neratinib for HER2-amplified cancer

Abstract A167: Targeting HER2 (ERBB2) amplification identified by next-generation sequencing (NGS) in patients with advanced or metastatic solid tumors

Abstract A012: Humanized patient-derived xenografts (PDXs) recapitulate clinical responses in microsatellite stable (MSS) and unstable (MSI-H) colorectal cancer (CRC)

Abstract A055: RSPO3 overexpression is a characteristic feature of signet ring gastrointestinal malignancies

Modeling of Patient-Derived Xenografts in Colorectal Cancer

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

Abstract C50: Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer

Abstract A36: Circulating cell-free DNA as a marker for response and resistance to BRAF and EGFR inhibition in BRAF-mutated metastatic colorectal cancer

Abstract A76: Prospective evaluation of two-phase NGS platform coupled to active precision oncology decision support in the therapeutic management of patients with advanced cancers

Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs

Cancer In Silico Drug Discovery: A Systems Biology Tool for Identifying Candidate Drugs to Target Specific Molecular Tumor Subtypes

Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations

Abstract B35: Acquired KRAS mutations after anti-EGFR therapy partially derive from low-frequency clones detectable in the primary tumor.

Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only